SCHEMBL23754834

SCHEMBL23754834

CNC(=O)c1ccccc1Nc1nc(Nc2ccc(OC)c(OC)c2)ncc1Br

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 6/20 0.63
▸ MAPK8 P45983 3/20 0.60
▸ MAPK9 P45984 1/20 0.60
▸ PRKAA2 P54646 1/20 0.59
▸ PRKAA1 Q13131 1/20 0.59
▸ ULK2 Q8IYT8 1/20 0.59
▸ PTK2 Q05397 6/20 0.59
▸ FGFR1 P11362 1/20 0.59
▸ FGFR2 P21802 1/20 0.59
▸ FGFR4 P22455 1/20 0.59
▸ FGFR3 P22607 1/20 0.59
▸ PKMYT1 Q99640 2/20 0.59
▸ ALK Q9UM73 2/20 0.54
▸ CDC7 O00311 1/20 0.54
▸ DAPK3 O43293 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ ROCK2 O75116 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ MAP4K4 O95819 1/20 0.54
▸ PAK4 O96013 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30086213 1.00 ULK1 (0.63) ULK1MAPK8MAPK9PRKAA2PRKAA1
SCHEMBL31174578 0.91 MAPK8 (0.62) ULK1MAPK8MAPK9PRKAA2PRKAA1
SCHEMBL17544689 0.91 PTK2 (0.72) ULK1MAPK8MAPK9PRKAA2PRKAA1
SCHEMBL30086170 0.91 PTK2 (0.72) ULK1MAPK8MAPK9PRKAA2PRKAA1
SCHEMBL23764852 0.88 PTK2 (0.66) ULK1MAPK8MAPK9PTK2PKMYT1
SCHEMBL19654194 0.88 ULK1 (0.65) ULK1MAPK8MAPK9PRKAA2PRKAA1
SCHEMBL23764855 0.87 MAPK8 (0.61) ULK1MAPK8PRKAA2PRKAA1ULK2
SCHEMBL30086370 0.87 MAPK8 (0.61) ULK1MAPK8PRKAA2PRKAA1ULK2
SCHEMBL23754825 0.87 ULK1 (0.59) ULK1MAPK8MAPK9PRKAA2PRKAA1
SCHEMBL30086246 0.87 ULK1 (0.59) ULK1MAPK8MAPK9PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
CN-115515589-A ULK1/2 inhibitors and methods of use thereof 萨克生物研究学院 2022-12-23 — — CN disclosed
EP-4103182-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Salk Institute for Biological Studies (US) 2022-12-21 — — EP disclosed
WO-2021163629-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 — — WO disclosed
WO-2021163629-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 ULK1 2/4885MAPK8 1702/4885MAPK9 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback